Literature DB >> 25001870

MALDI-TOF mass spectrometry: any use for Aspergilli?

Maurizio Sanguinetti1, Brunella Posteraro.   

Abstract

Recently, relentless efforts to develop rapid, cost-effective, and reliable laboratory methods for daily diagnosis of fungal diseases such as aspergillosis appear to be materialized in the relatively new, but revolutionary matrix-assisted laser desorption ionization-time-of-flight (MALDI-TOF) mass spectrometry (MS) technology. As for Aspergilli, MALDI-TOF MS profiling of isolates growing in culture--characteristic protein spectra are obtainable by means of simple and reproducible preanalytical and analytical procedures--ensures that single species within the different sections or complexes can be easily and accurately identified, including species that are morphologically and phylogenetically similar to each other. Thus, resort to longer and more onerous molecular biology techniques is restricted to those cases for which no spectra in the reference fungal database or library are available at the time of analysis. However, it is necessary to interrogate reference libraries composed of spectra that have been obtained using procedures similar to those used to obtain the test isolate's mass spectrum, as well as to continuously update these libraries for enriching them with fungal strains/species not (or not well) represented in their current versions. Compared to mold identification, very limited work was reported on the use of MALDI-TOF MS to perform strain typing or antifungal susceptibility testing for Aspergilli. If these complementing areas will be potentiated in the near future, MALDI-TOF MS could effectively support the clinical microbiology/mycology laboratory in its primary role of assisting either infection control specialists or physicians for the diagnosis and treatment of aspergillosis.

Entities:  

Mesh:

Year:  2014        PMID: 25001870     DOI: 10.1007/s11046-014-9757-1

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  52 in total

1.  Risks of "blind" automated identification systems in medical microbiology.

Authors:  Nicasio Mancini; Roberto Burioni; Maurizio Sanguinetti; Massimo Clementi
Journal:  J Clin Microbiol       Date:  2013-11       Impact factor: 5.948

2.  Ongoing revolution in bacteriology: routine identification of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  Piseth Seng; Michel Drancourt; Frédérique Gouriet; Bernard La Scola; Pierre-Edouard Fournier; Jean Marc Rolain; Didier Raoult
Journal:  Clin Infect Dis       Date:  2009-08-15       Impact factor: 9.079

3.  MALDI-TOF MS-based drug susceptibility testing of pathogens: the example of Candida albicans and fluconazole.

Authors:  Carine Marinach; Alexandre Alanio; Martine Palous; Stéphanie Kwasek; Arnaud Fekkar; Jean-Yves Brossas; Sophie Brun; Georges Snounou; Christophe Hennequin; Dominique Sanglard; Annick Datry; Jean-Louis Golmard; Dominique Mazier
Journal:  Proteomics       Date:  2009-10       Impact factor: 3.984

4.  Misidentification of Aspergillus nomius and Aspergillus tamarii as Aspergillus flavus: characterization by internal transcribed spacer, β-Tubulin, and calmodulin gene sequencing, metabolic fingerprinting, and matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Emily W T Tam; Jonathan H K Chen; Eunice C L Lau; Antonio H Y Ngan; Kitty S C Fung; Kim-Chung Lee; Ching-Wan Lam; Kwok-Yung Yuen; Susanna K P Lau; Patrick C Y Woo
Journal:  J Clin Microbiol       Date:  2014-01-22       Impact factor: 5.948

Review 5.  MALDI-TOF-MS-based species identification and typing approaches in medical mycology.

Authors:  Oliver Bader
Journal:  Proteomics       Date:  2013-01-21       Impact factor: 3.984

6.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry in clinical microbiology.

Authors:  Robin Patel
Journal:  Clin Infect Dis       Date:  2013-04-17       Impact factor: 9.079

Review 7.  Emerging moulds: epidemiological trends and antifungal resistance.

Authors:  Marisa H Miceli; Samuel A Lee
Journal:  Mycoses       Date:  2011-06-14       Impact factor: 4.377

8.  Discrimination of Aspergillus isolates at the species and strain level by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry fingerprinting.

Authors:  Justin M Hettick; Brett J Green; Amanda D Buskirk; Michael L Kashon; James E Slaven; Erika Janotka; Francoise M Blachere; Detlef Schmechel; Donald H Beezhold
Journal:  Anal Biochem       Date:  2008-06-05       Impact factor: 3.365

9.  Mould routine identification in the clinical laboratory by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  Carole Cassagne; Stéphane Ranque; Anne-Cécile Normand; Patrick Fourquet; Sandrine Thiebault; Chantal Planard; Marijke Hendrickx; Renaud Piarroux
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

10.  Aspergillus species identification in the clinical setting.

Authors:  S A Balajee; J Houbraken; P E Verweij; S-B Hong; T Yaghuchi; J Varga; R A Samson
Journal:  Stud Mycol       Date:  2007       Impact factor: 16.097

View more
  15 in total

Review 1.  Identification of Molds by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry.

Authors:  Maurizio Sanguinetti; Brunella Posteraro
Journal:  J Clin Microbiol       Date:  2016-11-02       Impact factor: 5.948

2.  Advances against aspergillosis: biology, host response, diagnosis and treatment.

Authors:  David S Askew; Dimitrios P Kontoyiannis; Karl V Clemons
Journal:  Mycopathologia       Date:  2014-10-07       Impact factor: 2.574

Review 3.  Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory.

Authors:  Deirdre L Church; Lorenzo Cerutti; Antoine Gürtler; Thomas Griener; Adrian Zelazny; Stefan Emler
Journal:  Clin Microbiol Rev       Date:  2020-09-09       Impact factor: 26.132

Review 4.  Azole Resistance in Aspergillus fumigatus in Patients with Cystic Fibrosis: A Matter of Concern?

Authors:  A Hamprecht; F Morio; O Bader; P Le Pape; J Steinmann; E Dannaoui
Journal:  Mycopathologia       Date:  2017-06-26       Impact factor: 2.574

5.  Susceptibility Testing of Common and Uncommon Aspergillus Species against Posaconazole and Other Mold-Active Antifungal Azoles Using the Sensititre Method.

Authors:  Enrica Mello; Brunella Posteraro; Antonietta Vella; Elena De Carolis; Riccardo Torelli; Tiziana D'Inzeo; Paul E Verweij; Maurizio Sanguinetti
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

Review 6.  Aspergillus fumigatus-Related Species in Clinical Practice.

Authors:  Frédéric Lamoth
Journal:  Front Microbiol       Date:  2016-05-17       Impact factor: 5.640

7.  Performance of VITEK mass spectrometry V3.0 for rapid identification of clinical Aspergillus fumigatus in different culture conditions based on ribosomal proteins.

Authors:  Longrong Zhou; Yongquan Chen; Yuanhong Xu
Journal:  Infect Drug Resist       Date:  2017-12-08       Impact factor: 4.003

8.  Evaluation of the Bruker Biotyper Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry System for Identification of Aspergillus Species Directly from Growth on Solid Agar Media.

Authors:  Ying Li; He Wang; Yu-Pei Zhao; Ying-Chun Xu; Po-Ren Hsueh
Journal:  Front Microbiol       Date:  2017-06-29       Impact factor: 5.640

Review 9.  A Review of Diagnostic Methods for Invasive Fungal Diseases: Challenges and Perspectives.

Authors:  Diego R Falci; Claudio M B Stadnik; Alessandro C Pasqualotto
Journal:  Infect Dis Ther       Date:  2017-03-29

Review 10.  Chronic Pulmonary Aspergillosis-Where Are We? and Where Are We Going?

Authors:  Gemma E Hayes; Lilyann Novak-Frazer
Journal:  J Fungi (Basel)       Date:  2016-06-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.